QUOTE AND NEWS
Benzinga  Apr 23  Comment 
In a report published Thursday, Wedbush analysts maintained a Neutral rating on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), with a price target of $104. The company is to report its 1Q15 results on April 30. The analysts expect the company to...
Market Intelligence Center  Apr 22  Comment 
MarketIntelligenceCenter.com’s patented option-trade picking algorithm found two trade ideas on BioMarin Pharmaceutical (BMRN) today after it traded between between $119.70 and $121.74 before closing at $121.24 on Tuesday. For more conservative...
Benzinga  Mar 30  Comment 
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the results of a post-hoc sub-analysis of the PKU-016 or ASCEND study, the largest randomized controlled trial evaluating neurocognitive outcomes in patients with phenylketonuria...
TheStreet.com  Mar 27  Comment 
NEW YORK (TheStreet) -- BioMarin Pharmaceutical shares are up 11.77% to $129.15 in trading on Friday after analysts at Deutsche Bank said that the company may be the latest biotech target.Fellow biotech company Shire is close to...
Forbes  Mar 27  Comment 
In trading on Friday, the First Trust NYSE Arca Biotechnology Index Fund ETF (FBT) is outperforming other ETFs, up about 2.9% on the day.  Components of that ETF showing particular strength include shares of Biomarin Pharma (BMRN), up about 13%...
FiercePharma  Mar 27  Comment 
The M&A rumor mill was churning Friday morning on reports of an in-the-works Shire ($SHPG) deal for orphan drugmaker BioMarin Pharmaceuticals.
FierceBiotech  Mar 27  Comment 
Shire is an acquisitive company with a focus on rare diseases. BioMarin fits the same description. A blog post that, by its own admission, "might be codswallop," reported that the former is considering buying the latter. And those three facts...
Benzinga  Mar 27  Comment 
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) jumped over 14 percent on Friday, as a buyout rumor surfaced just ahead of an apparently routine conference call with analysts concerning its developmental drug programs. Separately, Deutsche Bank's...
TheStreet.com  Mar 27  Comment 
NEW YORK (TheStreet) -- The shares of BioMarin are climbing after a blog reported last night that Shire is considering offering to acquire the company. Meanwhile, analysts at UBS and Deutsche raised their price targets for the orphan drug...




 

BioMarin Pharmaceutical Inc. (BMRN), a developer of enzyme-related therapies (ERT), co-markets Aldurazyme with Genzyme Corporation (GENZ) for the treatment of MPS-I (mucopolysaccharidosis). MPS-I is a rare genetic enzyme deficiency disorder, afflicting roughly 3,000 people worldwide, caused by the lack of a specific enzyme involved in lysosomal storage. More common names for mucopolysaccharidosis are Hurler's Syndrome, Hurler-Scheie, and Scheie's Disease. The company's other developed product, Naglazyme, for MPS-VI, recently entered the market. MPS-VI is also a rare genetic enzyme deficiency disorder, with an estimated 1,100 people suffering from it worldwide. The company's third lead drug, Kuvan, received FDA approval for the treatment of PKU in December 2007. With the recent launch of Kuvan, the company now has three products on the market. The company also receives royalties and license revenue on sales of the Orapred franchise from Alliant Pharmaceuticals. In 2004, the company acquired Orapred, a grape-flavored oral corticosteroid liquid for the treatment of severe asthma in children and subsequently licensed the franchise to Alliant Pharmaceuticals in March 2006. BioMarin, headquartered in Novato, CA, employs roughly 300 people.

Business Overview

Business & Financial Metrics

In 2009, BMRN incurred a net loss of $488 thousand on revenues of $324.7 million. This represents a real turnaround from 2008, when the company earned $30.8 million on $296.5 million in revenues.[1]

Geographical Distribution[2]

BioMarin generates the majority of its revenues from sales in Europe.

IMAGE:BMRN-Geography2009.jpg[2]

Competition

BioMarin competes with companies like:

References

  1. BMRN 2009 10-K pg. 36  
  2. 2.0 2.1 BMRN 2009 10-K pg. 16  
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki